Cancer · 2016 · 23 citations · 21 references
MedicineOncologyRadiation OncologyChemotherapyClinical Radiation OncologyStem Cell TransplantationAutologous Stem Cell TransplantationCell Therapy ToxicityChemotherapy In Hematologic MalignanciesHematologic Malignancy TherapyHigh-dose ChemotherapyRadiation TherapyAutologous Stem Cell TherapyHodgkin Lymphoma RadiotherapyHodgkin Lymphoma TreatmentPrimary Refractory LymphomaRadiotherapy CombinationsRefractory Hodgkin LymphomaRelapsed Hodgkin LymphomaTransplantation
BACKGROUND: No consensus exists regarding the use of radiotherapy (RT) in conjunction with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with relapsed/refractory classical Hodgkin lymphoma (HL). The objectives of the current study were to characterize practice patterns and assess the efficacy and toxicity of RT at 2 major transplantation centers. METHODS: Eligible patients underwent HDC/ASCT from 2006 through 2015 using the combination of either carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) or cyclophosphamide, BCNU, and etoposide (CBV). RESULTS: F]fluorodeoxyglucose (FDG)-avid at the time of HDC/ASCT. Disease recurrence occurring after HDC/ASCT was associated with primary refractory disease and FDG-avidity at the time of HDC/ASCT. RT was not found to be associated with LC, progression-free survival, or overall survival on univariate analysis. In a model incorporating primary refractory HL and FDG-avid disease at the time of HDC/ASCT, RT was found to be associated with a decreased risk of local disease recurrence (hazard ratio, 0.3; P = .02). In patients with primary refractory HL and/or FDG-avid disease at the time of HDC/ASCT, the 4-year LC rate was 81% with RT versus 49% without RT (P = .03). There was one case of Common Terminology Criteria for Adverse Events grade ≥ 3 RT-related toxicity (acute grade 3 pancytopenia). CONCLUSIONS: In patients undergoing ASCT for relapsed/refractory HL, peritransplantation RT was used more often for disease that was early stage, primary refractory, or FDG-avid after salvage conventional-dose chemotherapy. RT was associated with improved LC of high-risk localized disease and was well tolerated with modern techniques. Cancer 2017;123:1363-1371. © 2016 American Cancer Society.
21
Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text
Norbert Schmitz, Beate Pfistner, M. Sextro et al. · The Lancet · 2002 · 1.1K citations
Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text
Medicine, Immunology, Oncology +15
Lena Specht, Joachim Yahalom, Tim Illidge et al. · International Journal of Radiation Oncology*Biology*Physics · 2013 · 577 citations